Organon & Co. (OGN) stock
Close on Nov 18, 2026Market cap $3.66BP/E 18.1Yield 2.44%
Earnings
Organon's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Organon's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026before the open | $1.46B | -3.5% | $0.55 | $0.71 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 12, 2026before the open | $1.51B | -5.3% | -$0.79 | $0.63 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | $1.60B | +1.3% | $0.61 | $1.01 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $1.59B | -0.8% | $0.56 | $1.00 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025before the open | $1.51B | -6.7% | $0.33 | $1.02 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 13, 2025before the open | $1.59B | -0.4% | $0.42 | $0.90 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 31, 2024before the open | $1.58B | +4.1% | $1.38 | $0.87 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $1.61B | -0.1% | $0.75 | $1.12 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024before the open | $1.62B | +5.5% | $0.78 | $1.22 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 15, 2024before the open | $1.60B | +7.6% | $2.13 | $0.88 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | $1.52B | -1.2% | $0.23 | $0.87 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $1.61B | +1.5% | $0.95 | $1.31 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $1.54B | -1.9% | $0.69 | $1.08 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 16, 2023before the open | $1.49B | -7.4% | $0.42 | $0.81 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $1.54B | -3.9% | $0.89 | $1.32 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $1.59B | -0.6% | $0.92 | $1.25 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $1.57B | – | $1.36 | $1.65 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 17, 2022before the open | $1.60B | – | $0.79 | $1.37 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 12, 2021before the open | $1.60B | – | $1.27 | $1.67 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021before the open | $1.60B | – | $1.70 | $1.72 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Organon's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenue | FY2026 | $6.20B | – | New | Feb 12, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $1.90B | – | New | Feb 12, 2026 |
| Depreciationnon-GAAP | FY2026 | $140.00M | – | Lowered | Feb 12, 2026 |
| Effective non-GAAP tax ratenon-GAAP | FY2026 | 27.5% – 29.5% | – | New | Feb 12, 2026 |
| Ex-FX revenue growthnon-GAAP | FY2026 | -1.5% | – | New | Feb 12, 2026 |
| Fully diluted weighted average shares outstandingnon-GAAP | FY2026 | 265 | – | New | Feb 12, 2026 |
| FX translation impactnon-GAAP | FY2026 | $75.00M | – | Lowered | Feb 12, 2026 |
| Interestnon-GAAP | FY2026 | $500.00M | – | New | Feb 12, 2026 |
Guidance vs results
The last range Organon gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $6.20B – $6.25B | $6.22BΣ4Q | Within range |
| FY2025 | Revenue growth | -3.2% – -2.4% | -2.92%Σ4Q | Within range |
Guidance history
Every forecast Organon put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Feb 12, 2026 | Adjusted EBITDA | FY2026 | $1.90B | New |
| Feb 12, 2026 | Effective non-GAAP tax rate | FY2026 | 27.5% – 29.5% | New |
| Feb 12, 2026 | Fully diluted weighted average shares outstanding | FY2026 | 265 | New |
| Feb 12, 2026 | Interest | FY2026 | $500.00M | New |
| Feb 12, 2026 | Depreciation | FY2026 | $140.00M | Lowered |
| Feb 12, 2026 | FX translation impact | FY2026 | $75.00M | Lowered |
| Feb 12, 2026 | Ex-FX revenue growth | FY2026 | -1.5% | New |
| Feb 12, 2026 | revenue | FY2026 | $6.20B | New |
| Nov 10, 2025 | Adjusted gross margin | FY2025 | 60% – 61% | Reaffirmed |
| Nov 10, 2025 | Adjusted EBITDA margin (Non-GAAP) | FY2025 | 31% | New |
| Nov 10, 2025 | Fully diluted weighted average shares outstanding | FY2025 | 263 | Reaffirmed |
| Nov 10, 2025 | Effective non-GAAP tax rate | FY2025 | 22.5% – 24.5% | Reaffirmed |
| Nov 10, 2025 | Interest | FY2025 | $510.00M | Raised |
| Nov 10, 2025 | Depreciation | FY2025 | $135.00M | Lowered |
| Nov 10, 2025 | IPR&D* | FY2025 | $6.00M | Lowered |
| Nov 10, 2025 | Ex-FX revenue growth | FY2025 | -3.7% – -3.1% | Lowered |
| Nov 10, 2025 | Nominal revenue growth | FY2025 | -3.2% – -2.4% | New |
| Nov 10, 2025 | Revenue | FY2025 | $6.20B – $6.25B | Lowered |
| Aug 5, 2025 | Adjusted gross margin | FY2025 | 60% – 61% | New |
| Aug 5, 2025 | Fully diluted weighted average shares outstanding | FY2025 | 263 | New |
| Aug 5, 2025 | Interest | FY2025 | $510.00M | New |
| Aug 5, 2025 | Effective non-GAAP tax rate | FY2025 | 22.5% – 24.5% | Lowered |
| Aug 5, 2025 | Depreciation | FY2025 | $135.00M | Lowered |
| Aug 5, 2025 | Adjusted EBITDA margin (non-GAAP) | FY2025 | 31% – 32% | New |
| Aug 5, 2025 | Revenue | FY2025 | $6.28B – $6.38B | New |
| May 1, 2025 | Adjusted gross margin | FY2025 | 60% – 61% | New |
| May 1, 2025 | Adjusted EBITDA margin (Non-GAAP) | FY2025 | 31% – 32% | New |
| May 1, 2025 | Effective non-GAAP tax rate | FY2025 | 22.5% – 24.5% | Lowered |
| May 1, 2025 | Interest | FY2025 | $510.00M | New |
| May 1, 2025 | Depreciation | FY2025 | $135.00M | Lowered |
| May 1, 2025 | Revenue | FY2025 | $6.13B – $6.33B | Reaffirmed |
| Feb 13, 2025 | Adjusted EBITDA margin (Non-GAAP) | FY2025 | 31% – 32% | New |
| Feb 13, 2025 | Revenue | FY2025 | $6.13B – $6.33B | New |
| Oct 31, 2024 | Adjusted gross margin | FY2024 | 61.5% | Narrowed |
| Oct 31, 2024 | Adjusted EBITDA margin (non-GAAP) | FY2024 | 30% – 31% | Lowered |
| Oct 31, 2024 | Fully diluted weighted average shares outstanding | FY2024 | 259 | Reaffirmed |
| Oct 31, 2024 | Effective non-GAAP tax rate | FY2024 | 18.5% – 20.5% | Reaffirmed |
| Oct 31, 2024 | SG&A | FY2024 | $1.55B – $1.60B | Raised |
| Oct 31, 2024 | R&D | FY2024 | $430.00M – $470.00M | Lowered |
| Oct 31, 2024 | IPR&D | FY2024 | $81.00M | Lowered |
| Oct 31, 2024 | Total R&D | FY2024 | $510.00M – $550.00M | Raised |
| Oct 31, 2024 | Interest | FY2024 | $520.00M | Narrowed |
| Oct 31, 2024 | Depreciation | FY2024 | $130.00M | Lowered |
| Oct 31, 2024 | Revenues | FY2024 | $6.38B – $6.43B | Narrowed |
| Aug 6, 2024 | Adjusted gross margin | FY2024 | 61% – 63% | Reaffirmed |
| Aug 6, 2024 | Adjusted EBITDA margin (Non-GAAP) | FY2024 | 31% – 33% | New |
| Aug 6, 2024 | Fully diluted weighted average shares outstanding | FY2024 | 259 | Reaffirmed |
| Aug 6, 2024 | Effective non-GAAP tax rate | FY2024 | 18.5% – 20.5% | Reaffirmed |
| Aug 6, 2024 | SG&A | FY2024 | $1.50B – $1.70B | Raised |
| Aug 6, 2024 | R&D | FY2024 | $430.00M – $530.00M | Lowered |
| Aug 6, 2024 | Interest | FY2024 | $520.00M | Narrowed |
| Aug 6, 2024 | Depreciation | FY2024 | $130.00M | Lowered |
| Aug 6, 2024 | Revenues | FY2024 | $6.25B – $6.45B | New |
| May 2, 2024 | Adjusted gross margin | FY2024 | 61% – 63% | Reaffirmed |
| May 2, 2024 | Fully diluted weighted average shares outstanding | FY2024 | 259 | Reaffirmed |
| May 2, 2024 | Adjusted EBITDA margin (Non-GAAP) | FY2024 | 31% – 33% | Raised |
| May 2, 2024 | Effective non-GAAP tax rate | FY2024 | 18.5% – 20.5% | Lowered |
| May 2, 2024 | SG&A | FY2024 | $1.50B – $1.70B | Raised |
| May 2, 2024 | R&D* | FY2024 | $400.00M – $500.00M | Lowered |
| May 2, 2024 | Interest | FY2024 | $520.00M | Raised |
| May 2, 2024 | Depreciation | FY2024 | $130.00M | Lowered |
| May 2, 2024 | Revenues | FY2024 | $6.20B – $6.50B | Reaffirmed |
| Feb 15, 2024 | Adjusted EBITDA margin | FY2024 | 31% – 33% | New |
| Feb 15, 2024 | Adjusted gross margin | FY2024 | 61% – 63% | New |
| Feb 15, 2024 | Fully diluted weighted average shares outstanding | FY2024 | 259 | New |
| Feb 15, 2024 | Effective non-GAAP tax rate | FY2024 | 18.5% – 20.5% | New |
| Feb 15, 2024 | SG&A | FY2024 | $1.50B – $1.70B | New |
| Feb 15, 2024 | R&D (excluding IPR&D) | FY2024 | $400.00M – $500.00M | Lowered |
| Feb 15, 2024 | Interest | FY2024 | $520.00M | Raised |
| Feb 15, 2024 | Depreciation | FY2024 | $130.00M | Lowered |
| Feb 15, 2024 | Revenues | FY2024 | $6.20B – $6.50B | New |
| Nov 2, 2023 | Adjusted EBITDA margin | FY2023 | 30.5% – 31.5% | Lowered |
| Nov 2, 2023 | Revenues | FY2023 | $6.15B – $6.25B | Lowered |
| Aug 8, 2023 | Adjusted EBITDA margin | FY2023 | 31.5% – 33% | Raised |
| Aug 8, 2023 | revenue | FY2023 | $6.25B – $6.45B | Raised |
| May 4, 2023 | Adjusted EBITDA margin | FY2023 | 31% – 33% | Reaffirmed |
| May 4, 2023 | Fully diluted weighted average shares outstanding | FY2023 | 257 | New |
| May 4, 2023 | Effective non-GAAP tax rate | FY2023 | 19% – 21% | New |
| May 4, 2023 | Interest | FY2023 | $515.00M | New |
| May 4, 2023 | Depreciation | FY2023 | $130.00M | Lowered |
| May 4, 2023 | Revenues | FY2023 | $6.15B – $6.45B | Reaffirmed |
| Feb 16, 2023 | Adjusted EBITDA margin | FY2023 | 31% – 33% | New |
| Feb 16, 2023 | Revenues | FY2023 | $6.15B – $6.45B | New |
| Nov 3, 2022 | Adjusted EBITDA margin | FY2022 | 33.5% – 34.5% | Raised |
| Nov 3, 2022 | Revenue | FY2022 | $6.10B – $6.20B | Lowered |
| Aug 4, 2022 | Adjusted EBITDA margin | FY2022 | 32% – 34% | Lowered |
| Aug 4, 2022 | revenue | FY2022 | $6.10B – $6.30B | Lowered |
| May 5, 2022 | Adjusted EBITDA margin | FY2022 | 34% – 36% | Reaffirmed |
| May 5, 2022 | Fully diluted weighted avg. shares outstanding | FY2022 | 255 | Reaffirmed |
| May 5, 2022 | Effective Non-GAAP tax rate | FY2022 | 17.5% – 19.5% | Reaffirmed |
| May 5, 2022 | Interest | FY2022 | $400.00M | Raised |
| May 5, 2022 | Depreciation | FY2022 | $100.00M – $115.00M | Lowered |
| May 5, 2022 | Revenue | FY2022 | $6.10B – $6.40B | Reaffirmed |
| Feb 17, 2022 | Adjusted EBITDA margins | FY2022 | 34% – 36% | New |
| Feb 17, 2022 | Fully diluted weighted avg. shares outstanding | FY2022 | 255 | New |
| Feb 17, 2022 | Effective Non-GAAP tax rate | FY2022 | 17.5% – 19.5% | New |
| Feb 17, 2022 | Interest expense | FY2022 | $400.00M | New |
| Feb 17, 2022 | Depreciation | FY2022 | $100.00M – $115.00M | Lowered |
| Feb 17, 2022 | revenue | FY2022 | $6.10B – $6.40B | New |
| Nov 12, 2021 | Adjusted EBITDA margin | FY2021 | 36.5% – 37.5% | Narrowed |
| Nov 12, 2021 | Fully diluted weighted avg. shares outstanding | FY2021 | 254 | Reaffirmed |
| Nov 12, 2021 | Effective Non-GAAP tax rate | FY2021 | 17.5% – 19.5% | Reaffirmed |
| Nov 12, 2021 | Interest | FY2021 | $400.00M | Raised |
| Nov 12, 2021 | Depreciation (*) | FY2021 | $100.00M – $115.00M | Lowered |
| Nov 12, 2021 | Revenue | FY2021 | $6.20B – $6.30B | Narrowed |
| Aug 12, 2021 | Adjusted EBITDA margin | FY2021 | 36% – 38% | New |
| Aug 12, 2021 | Weighted avg. shares outstanding | FY2021 | 254 | New |
| Aug 12, 2021 | Effective Non-GAAP tax rate | FY2021 | 17.5% – 19.5% | New |
| Aug 12, 2021 | Interest | FY2021 | $400.00M | New |
| Aug 12, 2021 | Depreciation | FY2021 | $100.00M – $115.00M | Lowered |
| Aug 12, 2021 | Revenue | FY2021 | $6.10B – $6.40B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Organon filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- News
- Results
- Results
- News
- Results
- Results
- Update
See a number that looks wrong?